How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,960 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

13821. Tight junction-associated proteins (occludin, ZO-1, claudin-1, claudin-4) in squamous cell carcinoma and Bowen's disease. (Abstract)

disorders of keratinization.Expression of the proteins in normal human epidermis, five cases of squamous cell carcinoma (SCC) of the skin and five cases of Bowen's disease (BD) was examined by immunofluorescence staining.In normal human epidermis, occludin, ZO-1 and claudin-4 were expressed at the cell-cell borders in the granular layer specifically or dominantly, whereas claudin-1 was expressed in the whole epithelium. In SCC, occludin, ZO-1, claudin-1 and claudin-4 were strongly expressed in tumour (...) Tight junction-associated proteins (occludin, ZO-1, claudin-1, claudin-4) in squamous cell carcinoma and Bowen's disease. The epidermis, which is a typical stratified epithelium, has tight junctions (TJs) in the granular layer, as do simple epithelia. So far, abnormalities of TJs and involvement of claudin-1 have been reported in tumours of simple epithelia.To examine the expression of TJ-associated proteins (occludin, ZO-1, claudin-1 and claudin-4) in normal human epidermis and in malignant

2004 British Journal of Dermatology

13822. Multiple squamous cell carcinomas in a patient with mycosis fungoides. (Abstract)

Multiple squamous cell carcinomas in a patient with mycosis fungoides. A 51-year-old man with type IV skin presented for evaluation of a generalized rash associated with multiple ulcerated, nodular lesions on his legs. The nodular lesions occurred approximately 18 months after the initial onset of generalized rash, which had been diagnosed as plaque/patch stage mycosis fungoides. He continued to develop further nodular lesions on his trunk in the weeks following presentation. The nodular (...) lesions were shown to be squamous-cell carcinoma on histopathology. He had received only topical hydrocortisone prior to the development of the second cutaneous malignancy and had no past exposure to carcinogens. His squamous cell carcinomas were treated with surgical excision and split-skin grafting. He received total skin electron-beam therapy to treat the mycosis fungoides. Second malignancy in mycosis fungoides is a recognized phenomenon and usually occurs after potentially carcinogenic therapy

2005 Australasian Journal of Dermatology

13823. Defining patients with high-risk cutaneous squamous cell carcinoma. (Abstract)

Defining patients with high-risk cutaneous squamous cell carcinoma. SUMMARY Non-melanoma skin cancers occur at an epidemic rate in Australia. With an ageing population more Australians will develop these cancers and at an increasing rate. In the majority of cases, local treatment, usually excision, is highly curative. However, a subset of the population are diagnosed with a high-risk cutaneous squamous cell carcinoma, defined as a patient having a higher risk of subclinical metastases (...) to regional lymph nodes based on unfavourable primary lesion features and patient factors. Despite treatment, patients developing metastatic cutaneous squamous cell carcinoma experience mortality and morbidity usually as a consequence of uncontrolled metastatic nodal disease. It is therefore important that clinicians treating skin cancers have an understanding and awareness of these high-risk patients. The aim of this article is to discuss the features that define a high-risk patient and to present some

2006 Australasian Journal of Dermatology

13824. Retinoic acid suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma. (Abstract)

Retinoic acid suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma. Activation of telomerase is crucial for the continued growth and progression of cancer cells. In a previous study, we showed that telomerase is frequently activated in skin tumours.Because retinoic acid (RA) plays an important role in the growth and differentiation of keratinocytes and as RA has some preventive and therapeutic effects on human skin cancers, we examined the effect of RA (...) on the telomerase activity of HSC-1 human cutaneous squamous cell carcinoma cells.Treatment of HSC-1 cells with all-trans RA (ATRA) significantly suppressed their telomerase activity. The suppression of telomerase activity was obvious at day 4 and was maximal at day 5 after the start of treatment with RA. This suppression was reversible as removal of ATRA allowed the recovery of telomerase activity. The suppression of telomerase activity correlated with the decreased expression of mRNA of human telomerase

2005 British Journal of Dermatology

13825. The squamous cell carcinoma antigens as relevant biomarkers of atopic dermatitis. (Abstract)

The squamous cell carcinoma antigens as relevant biomarkers of atopic dermatitis. Although it is thought that both Th1- and Th2-type inflammations are involved in the pathogenesis of atopic dermatitis (AD), it is controversial which immune response is more involved in regulating the clinical severity of AD. We recently found that the squamous cell carcinoma antigens 1 (SCCA1) and SCCA2 are novel biomarkers of bronchial asthma, downstream of IL-4 and IL-13.We examined whether SCCA1 and SCCA2 (...) could also serve as biomarkers of AD, reflecting its Th2-type immune responses, and whether the expression level of SCCA was correlated with clinical severity of AD.We compared the expression of SCCA1 and SCCA2 at the mRNA and protein levels in both involved and uninvolved skin of AD patients and in normal control skin. We next analysed induction of SCCA by IL-4 or IL-13 in keratinocytes. Finally, we compared the serum level of SCCA with laboratory parameters reflecting Th2-type inflammation

2005 Clinical and Experimental Allergy

13826. Rhabdoid phenotype in cutaneous squamous carcinoma: an earlier report! Full Text available with Trip Pro

Rhabdoid phenotype in cutaneous squamous carcinoma: an earlier report! 11477129 2001 08 30 2008 11 20 0021-9746 54 8 2001 Aug Journal of clinical pathology J. Clin. Pathol. Rhabdoid phenotype in cutaneous squamous carcinoma: an earlier report! 656 Pai S A SA Borges A M AM Soman C S CS eng Case Reports Comment Letter England J Clin Pathol 0376601 0021-9746 AIM IM J Clin Pathol. 2000 Nov;53(11):868-70 11127272 Aged Aged, 80 and over Carcinoma, Squamous Cell pathology Humans Male Neoplasms (...) , Multiple Primary pathology Phenotype Rhabdoid Tumor pathology Skin Neoplasms pathology 2001 7 31 10 0 2001 8 31 10 1 2001 7 31 10 0 ppublish 11477129 PMC1731500

2001 Journal of Clinical Pathology

13827. Acute toxicity and cost analysis of a phase III randomized trial of accelerated and conventional radiotherapy for squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group study. (Abstract)

controlled trial which compared accelerated radiotherapy (ART) with conventional radiotherapy (CRT) in stage III and IV squamous cell carcinoma (SCC) of the head and neck. Patients were randomized to either 59.4 Gy in 33 fractions over 24 days (ART) or to 70 Gy 35 fractions over 49 days (CRT) after being stratified for site and stage. Accrual began in 1991 and the trial was closed on 3 April 1998 with the targeted 350 patients. The 3-year survival for the whole group was 54%, and the 3-year disease-free (...) Acute toxicity and cost analysis of a phase III randomized trial of accelerated and conventional radiotherapy for squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group study. The primary purpose of the present analysis was to assess the feasibility and acute toxicity of a pure accelerated fractionation regimen in a cooperative group setting. This analysis included the first 320 patients entered on to the Trans-Tasman Radiation Oncology Group (TROG) randomized

1999 Australasian radiology Controlled trial quality: uncertain

13828. Gene-drug interaction at the glucocorticoid receptor increases risk of squamous cell skin cancer. Full Text available with Trip Pro

Gene-drug interaction at the glucocorticoid receptor increases risk of squamous cell skin cancer. Non-melanoma skin cancers (NMSCs) are the most common malignancy among US Caucasians. Using a population-based study of NMSC we found that oral steroid use is associated with nearly 6-fold elevated risk of squamous cell carcinoma among individuals with a common genetic variant in the steroid receptor (NR3C1) gene. Given the large numbers of individuals on immunosuppressive drug therapy

2007 Journal of Investigative Dermatology

13829. Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

carcinoma of the skin. The safety of this treatment will also be studied Condition or disease Intervention/treatment Phase Recurrent Skin Cancer Squamous Cell Carcinoma of the Skin Drug: Gefitinib Radiation: Radiotherapy Procedure: Conventional surgery Other: laboratory biomarker analysis Phase 2 Detailed Description: PRIMARY OBJECTIVES: I. Early progression rate (progression during ZD1839 induction). II. Feasibility of induction ZD1839 (for all patients) and concomitant ZD1839 with radiotherapy (...) : All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Within 12 weeks (+/- 2 weeks) prior to study entry, patients must have histologically or cytologically confirmed squamous cell carcinoma (SCC) of skin that is either locally advanced or recurrent with measurable disease; if the biopsy was collected outside of MDACC, the MDACC Pathology Department must assess and confirm the SCC diagnosis Patients may have previous surgical intervention with residual or recurrent disease Eastern

2005 Clinical Trials

13830. Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Condition or disease Intervention/treatment Phase Recurrent Skin Cancer Squamous Cell Carcinoma of the Skin Stage 0 Chronic Lymphocytic Leukemia Stage I Chronic Lymphocytic Leukemia Drug: dasatinib Other: laboratory biomarker analysis Phase 2 Detailed Description: PRIMARY OBJECTIVES: I. Determine the objective response rate (complete response and partial response) in patients with unresectable (...) or metastatic squamous cell carcinoma of the skin or RAI stage 0-I chronic lymphocytic leukemia receiving dasatinib. SECONDARY OBJECTIVES: I. Determine the progression-free survival of patients receiving this drug. II. Evaluate tumor for presence of total EphA2 and both total and active Src and FAK by immunohistochemistry (IHC) pre-treatment with dasatinib. III. Evaluate tumor for presence of cyclooxygenase-2 by IHC pre-treatment with dasatinib. OUTLINE: Patients are assigned to 1 of 2 treatment arms. ARM I

2007 Clinical Trials

13831. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. (Abstract)

Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. Although animal studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, may protect against cutaneous squamous cell carcinoma (SCC) and actinic keratoses (AKs), possible effects on keratinocytic cancers in humans are unknown.We sought to examine the relationship between ingestion of NSAIDs and the risk of SCC and AKs in humans.We conducted a case-control

2005 Journal of American Academy of Dermatology

13832. Mortality risk from squamous cell skin cancer. (Abstract)

Mortality risk from squamous cell skin cancer. To identify nonmelanoma skin cancer patients with squamous cell carcinoma (SCC) who are at greatest risk of disease-specific mortality.Prospectively enrolled patients with a minimum of one pathologically confirmed skin SCC lesion, definitive treatment of the SCC lesion(s) resulting in no evidence of disease, and at least 2 months of follow-up after definitive treatment were eligible for the present longitudinal analysis. They received comprehensive (...) clinical, pathologic evaluations and follow-up for patterns of failure and mortality.We enrolled 210 patients (187 men and 23 women) with a total of 277 skin SCC lesions and a median enrollment age of 68 years (range, 34 to 95 years). Median follow-up of surviving patients was 22 months. Three-year overall and disease-specific survival (DSS) rates were 70% and 85%, respectively. In univariate analyses, the clinical-pathologic factors associated with adverse DSS were local recurrence at presentation (P

2005 Journal of Clinical Oncology

13833. Acitretin induces apoptosis through CD95 signalling pathway in human cutaneous squamous cell carcinoma cell line SCL-1 Full Text available with Trip Pro

Acitretin induces apoptosis through CD95 signalling pathway in human cutaneous squamous cell carcinoma cell line SCL-1 Skin cancers are by far the most common human malignancies. Retinoids have shown promising preventive and therapeutic effects against a variety of human malignancies. The aim of this study was to investigate the apoptosis-inducing effect of acitretin on human skin squamous cell carcinoma (SCC) SCL-1 cells. We found that acitretin preferentially inhibited the growth of SCL-1 (...) inhibitor effectively suppressed acitretin-induced apoptosis whereas caspase-9 inhibitor did not. Acitretin increased the levels of CD95 (Fas), CD95-ligand and Fas-associated death domain. Neutralizing ZB4 anti-Fas antibody significantly inhibited the apoptosis in SCL-1 cells induced by acitretin. These results suggest that acitretin is able to induce apoptosis in skin cancer cells possibly via death receptor CD95 apoptosis pathway without affecting the viability of normal keratinocyte.

2008 Journal of cellular and molecular medicine

13834. Increased expression of an epidermal stem cell marker, cytokeratin 19, in cutaneous squamous cell carcinoma. (Abstract)

Increased expression of an epidermal stem cell marker, cytokeratin 19, in cutaneous squamous cell carcinoma. Cytokeratin 19 (CK19) has been considered to be a putative marker for epidermal stem cells in the hair follicle bulge. Cumulative reports have shown that epidermal stem cells play an important role in skin carcinogenesis. However, to date there has been no report on the clinical alteration of the stem cells in squamous cell carcinoma (SCC).To investigate alteration of the stem cells (...) and proliferating cells and to assess their relationship and potential contribution to SCC.Thirty paraffin-embedded neoplastic skin lesions, consisting of 10 cases each of actinic keratosis (AK), Bowen disease (BD) and SCC, were examined immunohistologically for CK19 and Ki-67.Positive reactivity for CK19 was seen in 30% of AK, 50% of BD and 80% of SCC lesions. There was significantly higher expression levels of CK19 in SCC than in AK and BD (P < 0.05). In addition, BD lesions harboured a significantly higher

2008 British Journal of Dermatology

13835. Squamous cell carcinoma with rhabdoid phenotype and osteoclast-like giant cells in a renal-pancreas transplant recipient. Full Text available with Trip Pro

Squamous cell carcinoma with rhabdoid phenotype and osteoclast-like giant cells in a renal-pancreas transplant recipient. Squamous cell carcinoma (SCC) is the commonest non-melanotic malignant skin tumour encountered after solid-organ transplantation. In this setting it is associated with a worse prognosis than sun-damage-induced SCC. Rhabdoid cells and osteoclastic giant cells are infrequently seen in SCC. This case highlights the unusual occurrence of rhabdoid cells and osteoclastic giant (...) cells in a post-transplant SCC.

2006 Journal of Clinical Pathology

13836. Test Characteristics of High-Resolution Ultrasound in the Preoperative Assessment of Margins of Basal Cell and Squamous Cell Carcinoma in Patients Undergoing Mohs Micrographic Surgery. Full Text available with Trip Pro

Test Characteristics of High-Resolution Ultrasound in the Preoperative Assessment of Margins of Basal Cell and Squamous Cell Carcinoma in Patients Undergoing Mohs Micrographic Surgery. Noninvasive techniques to assess subclinical spread of nonmelanoma skin cancer (NMSC) may improve surgical precision. High-resolution ultrasound has shown promise in evaluating the extent of NMSC.To determine the accuracy of high-resolution ultrasound to assess the margins of basal cell (BCC) and squamous cell (...) carcinomas (SCC) before Mohs micrographic surgery (MMS).We enrolled 100 patients with invasive SCC or BCC. Before the first stage of MMS, a Mohs surgeon delineated the intended surgical margin. Subsequently, a trained ultrasound technologist independently evaluated disease extent using the EPISCAN I-200 to evaluate tumor extent beyond this margin. The accuracy of high-resolution ultrasound was subsequently tested by comparison with pathology from frozen sections.The test characteristics of the high

2008 Dermatologic Surgery

13837. Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions Full Text available with Trip Pro

Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions Squamous cell carcinoma (SCC) of the skin is the most aggressive form of non-melanoma skin cancer (NMSC), and is the single most commonly diagnosed cancer in the U.S., with over one million new cases reported each year. Recent studies have revealed an oncogenic role of activated signal transducer and activator of transcription 3 (Stat3) in many human tumors, especially in those of epithelial (...) origin, including skin SCC. Stat3 is a mediator of numerous growth factor and cytokine signaling pathways, all of which activate it through phosphorylation of tyrosine 705.To further address the role of Stat3 in skin SCC tumorigenesis, we have analyzed a panel of human skin-derived cell lines ranging from normal human epidermal keratinocytes (NHEK), to non-tumorigenic transformed skin cells (HaCaT), to highly tumorigenic cells (SRB1-m7 and SRB12-p9) and observed a positive correlation between Stat3

2006 Molecular Cancer

13838. Do Langerhans cells play a role in vulvar epithelium resistance to squamous cell carcinoma? Full Text available with Trip Pro

Do Langerhans cells play a role in vulvar epithelium resistance to squamous cell carcinoma? Langerhans cells (LCs) are a very important part of the skin immune system.Skin biopsies taken from 13 women after the removal of vulvar squamous cell carcinoma (SCC) who had not been treated earlier for any vulvar diseases were investigated. The control group consisted of 12 women who underwent a plastic surgical operation of the vulva region. Immunohistochemical staining was performed on formalin-fixed (...) contribute to the prophylaxis and treatment of skin and mucosa carcinomas.

2007 Archivum Immunologiae et Therapiae Experimentalis

13839. Basal Cell and Squamous Cell Carcinoma Occurring within a Field of Multiple Tumors of the Follicular Infundibulum. (Abstract)

Presbyterian Medical Center, New York, NY, USA. jmacgregor@skincarephysicians.net Campanelli Carmen C Friedman Peter C PC Desciak Edward E eng Case Reports Journal Article 2008 09 23 United States Dermatol Surg 9504371 1076-0512 IM Aged Carcinoma, Basal Cell pathology Carcinoma, Squamous Cell pathology Facial Neoplasms pathology Humans Male Neoplasms, Multiple Primary pathology Skin Neoplasms pathology 2008 10 1 9 0 2008 12 19 9 0 2008 10 1 9 0 ppublish 18823351 DSU34324 10.1111/j.1524-4725.2008.34324.x (...) Basal Cell and Squamous Cell Carcinoma Occurring within a Field of Multiple Tumors of the Follicular Infundibulum. 18823351 2008 12 18 2008 11 21 1524-4725 34 11 2008 Nov Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] Dermatol Surg Basal cell and squamous cell carcinoma occurring within a field of multiple tumors of the follicular infundibulum. 1567-70 10.1111/j.1524-4725.2008.34324.x MacGregor Jennifer L JL Department of Dermatology, Columbia

2008 Dermatologic Surgery

13840. Squamous cell carcinoma induced by ultraviolet radiation originates from cells of the hair follicle in mice. (Abstract)

Squamous cell carcinoma induced by ultraviolet radiation originates from cells of the hair follicle in mice. Short-wave ultraviolet radiation (UVB) is the most carcinogenic part of the ultraviolet spectrum. The target cells of skin cancer are believed to be the bulge stem cells and/or their offspring, the transit-amplifying cells that reside in the epidermis. However, the amount of UVB penetrating epidermis and reaching the bulge cells is very low, which questions if these cells suffer (...) sufficient DNA damage to transform into cancer stem cells. We performed this study to determine whether UV-induced squamous cell carcinoma (SCC) originates from the epidermis or the hair follicles in mice. Hairless mice had their epidermis removed at different levels using CO(2) laser ablation. Simulated solar irradiations were administered either preoperatively (in total 7 weeks) or pre- and postoperatively (in total 30 weeks). Control groups were untreated or treated only with solar-simulated radiation

2007 Experimental Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>